35Pharma

Privately held: no public share price · Canada

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Activin receptor type IIA (ActRIIA)Peptide
Heart FailurePulmonary Arterial Hypertension

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
HS235Phase 1/2Pulmonary Arterial Hypertension
Est. primary completion 2028-03 · NCT07143448 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
HS235Phase 1/2Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Est. primary completion 2029-01 · NCT07123779 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.